177 Lutetium FPI 1835

N/A

Report date: 2025/11/21 17:15:25

Base Information

Drug Name177 Lutetium FPI 1835

Drug Alias Name[177Lu]-FPI-1835FPI-1835

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[5]

Mechanisms of ActionIonising radiation emittersBacterial beta-lactamase TEM inhibitors

TargetsBacterial beta-lactamase TEM

Therapy Area/IndicationsSarcoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFusion Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsSarcoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A